Skip to main content


Log in

Initial Experiences of Palliative Stereotactic Radiosurgery for Recurrent Brain Lymphomas

  • Clinical Study
  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript


In Kyoto University Hospital, stereotactic radiosurgery (SRS) has been performed for its rapid palliative effect in patients with recurrent primary central nervous system lymphoma (PCNSL), often in combination with salvage chemotherapy. In the present study, the treatment outcome and toxicity of SRS for recurrent PCNSL was retrospectively evaluated. Between March 1998 and June 2004, 17 histologically proven recurrent PCNSLs in nine patients were treated with linac-based stereotactic radiosurgery. All patients had developed intracranial recurrences after initial treatment including external beam radiation therapy (EBRT). The prescribed dose was 10.0–16.0 (median 12.0) Gy. Seven of nine patients received systemic chemotherapy around the time of SRS. The target volume was 0.4–24.5 ml (median 3.5 ml). Initial tumor response could be evaluated in 15 of 17 lesions. Among them, radiological complete response (CR), partial response (PR), stable disease (SD) and progressive disease (PD) was observed in 3, 10, 2, and 0 lesions, respectively. One-year overall survival rate and relapse-free survival rate after first SRS was 58% and 22%, respectively. Improvement of symptoms was observed in six patients. The time from SRS to symptomatic relief was 1–57 days (median 3 days). No ≥ grade 2 acute toxicities related to SRS were observed. In conclusion, linac-based SRS with a prescription dose of 10–12 Gy for recurrent PCNSL is useful for palliation, especially considering the short time, rapid tumor response, and low treatment toxicity.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others


  1. HA Fine and RJ Mayer, Primary central nervous system lymphoma. Ann Intern Med 119 (1993) 1093-1104

    PubMed  CAS  Google Scholar 

  2. SR Plotkin and TT Batchelor, Primary nervous-system lymphoma. Lancet Oncol 2 (2001) 354-365

    Article  PubMed  CAS  Google Scholar 

  3. AJ Ferreri, LE Abrey, JY Blay, B Borisch, J Hochman, EA Neuwelt, J Yahalom, E Zucca, F Cavalli, J Armitage and T Batchelor, Summary statement on primary central nervous system lymphomas from the Eighth International Conference on Malignant Lymphoma, Lugano, Switzerland, June 12 to 15, 2002. J Clin Oncol 21 (2003) 2407-2414

    Article  PubMed  Google Scholar 

  4. GA Sanden van den, LJ Schouten, JA Dijck van, JP Andel van, RW Maazen van der and JW Coebergh, Working Group of Specialists in Neuro-Oncology in the Southern, Eastern Netherlands: Primary central nervous system lymphomas: incidence and survival in the Southern and Eastern Netherlands. Cancer 94 (2002) 1548-1556

    Article  PubMed  Google Scholar 

  5. H Ishikawa, M Hasegawa, Y Tamaki, K Hayakawa, T Akimoto, H Sakurai, N Mitsuhashi, H Niibe, M Tamura and T Nakano, Comparable outcomes of radiation therapy without high-dose methotrexate for patients with primary central nervous system lymphoma. Jpn J Clin Oncol 33 (2003) 443-449

    Article  PubMed  Google Scholar 

  6. Y Shibamoto, E Tsuchida, K Seki, N Oya, M Hasegawa, Y Toda, M Takemoto, M Sumi, J Hiratsuka, M Oguchi, M Hosono, S Yasuda, M Sougawa, Y Kakutoh and N Hayabuchi, Primary central nervous system lymphoma in Japan 1995–1999: changes from the preceding 10 years. J Cancer Res Clin Oncol 130 (2004) 351-356

    Article  PubMed  Google Scholar 

  7. EM Bessell, A Lopez-Guillermo, S Villa, E Verger, B Nomdedeu, J Petit, P Byrne, E Montserrat and F Graus, Importance of radiotherapy in the outcome of patients with primary CNS lymphoma: an analysis of the CHOD/BVAM regimen followed by two different radiotherapy treatments. J Clin Oncol 20 (2001) 231-236

    Article  Google Scholar 

  8. EM Bessell, F Graus, A Lopez-Guillermo, S Villa, E Verger, J Petit, I Holland and P Byrne, CHOD/BVAM regimen plus radiotherapy in patients with primary CNS non-Hodgkin’s lymphoma. Int J Radiat Oncol Biol Phys 50 (2001) 457-464

    Article  PubMed  CAS  Google Scholar 

  9. T Cheng, P Forsyth, A Chaudhry, D Morris, S Gluck, JA Russell and DA Stewart, High-dose thiotepa, busulfan, cyclophosphamide and ASCT without whole-brain radiotherapy for poor prognosis primary CNS lymphoma. Bone Marrow Transplant 31 (2003) 679-685

    Article  PubMed  CAS  Google Scholar 

  10. PM Poortmans, HC Kluin-Nelemans, H Haaxma-Reiche, M Van't Veer, M Hansen, P Soubeyran, M Taphoorn, J Thomas, M Bent Van den, M Fickers, G Imhoff Van, C Rozewicz, I Teodorovic and M Glabbeke van, European Organization for Research, Treatment of Cancer Lymphoma Group: High-dose methotrexate-based chemotherapy followed by consolidating radiotherapy in non-AIDS-related primary central nervous system lymphoma: European Organization for Research and Treatment of Cancer Lymphoma Group Phase II Trial 20962. J Clin Oncol 21 (2003) 4483-4488

    Article  PubMed  CAS  Google Scholar 

  11. T Watanabe, Y Katayama, A Yoshino, C Komine, T Yokoyama and T Fukushima, Long-term remission of primary central nervous system lymphoma by intensified methotrexate chemotherapy. J Neurooncol 63 (2003) 87-95

    Article  PubMed  Google Scholar 

  12. L Plasswilm, U Herrlinger, A Korfel, M Weller, W Kuker, L Kanz, E Thiel and M Bamberg, Primary central nervous system (CNS) lymphoma in immunocompetent patients. Ann Hematol 81 (2002) 415-423

    Article  PubMed  CAS  Google Scholar 

  13. Y Shibamoto, N Hayabuchi, J Hiratsuka, S Tokumaru, H Shirato, M Sougawa, N Oya, Y Uematsu and M Hiraoka, Is whole-brain irradiation necessary for primary central nervous system lymphoma? Patterns of recurrence after partial-brain irradiation. Cancer 97 (2003) 128-133

    Article  PubMed  Google Scholar 

  14. M Reni, AJ Ferreri and E Villa, Second-line treatment for primary central nervous system lymphoma. Br J Cancer 79 (1999) 530-534

    Article  PubMed  CAS  Google Scholar 

  15. M Reni and AJ Ferreri, Therapeutic management of refractory or relapsed primary central nervous system lymphomas. Ann Hematol 80 (2001) B113-117

    Article  PubMed  CAS  Google Scholar 

  16. E Arellano-Rodrigo, A Lopez-Guillermo, EM Bessell, B Nomdedeu, E Montserrat and F Graus, Salvage treatment with etoposide (VP-16), ifosfamide and cytarabine (Ara-C) for patients with recurrent primary central nervous system lymphoma. Eur J Haematol 70 (2003) 219-224

    Article  PubMed  CAS  Google Scholar 

  17. Radiation Therapy Oncology Group: RTOG 95-07 Phase I Study OF Topotecan Plus Cranial Radiation for Glioblastoma Multiforme (NSC #609699) Appendix II Neurologic Function (NF) Status

  18. Y Dong, L Pan, B Wang, E Wang, N Zhang, P Cai and J Dai, Stereotactic radiosurgery in the treatment of primary central nervous system lymphoma. Chin Med J (Engl) 116 (2003) 1166-1170

    Google Scholar 

  19. RM Tyson, T Siegal, ND Doolittle, C Lacy, DF Kraemer and EA Neutwelt, Current status and future of relapsed primary central nervous system lymphoma (PCNSL). Leuk Lymphoma 44 (2003) 627-633

    Article  PubMed  CAS  Google Scholar 

  20. SL Stafford, BE Pollock, RL Foote, DA Gorman, DF Nelson and PJ Schomberg, Stereotactic radiosurgery for recurrent ependymoma. Cancer 88 (2000) 870-875

    Article  PubMed  CAS  Google Scholar 

  21. RS Hudes, BW Corn, M Werner-Wasik, D Andrews, J Rosenstock, L Thoron, B Downes and WJ Curran Jr, A phase I dose escalation study of hypofractionated stereotactic radiotherapy as salvage therapy for persistent or recurrent malignant glioma. Int J Radiat Oncol Biol Phys 43 (1999) 293-298

    Article  PubMed  CAS  Google Scholar 

  22. E Alexander III and JS Loeffler, Radiosurgery for primary malignant brain tumors. Semin Surg Oncol 14 (1998) 43-52

    Article  PubMed  Google Scholar 

  23. JM Varlotto, JC Flickinger, A Niranjan, AK Bhatnagar, D Kondziolka and LD Lunsford, Analysis of tumor control and toxicity in patients who have survived at least one year after radiosurgery for brain metastases. Int J Radiat Oncol Biol Phys 57 (2003) 452-464

    Article  PubMed  Google Scholar 

  24. C Soussain, F Suzan, K Hoang-Xuan, N Cassoux, V Levy, N Azar, C Belanger, E Achour, V Ribrag, S Gerber, JY Delattre and V Leblond, Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma. J Clin Oncol 19 (2001) 742-749

    PubMed  CAS  Google Scholar 

  25. M Reni, W Mason, F Zaja, J Perry, E Franceschi, D Bernardi, S Dell’Oro, C Stelitano, M Candela, A Abbadessa, A Pace, R Bordonaro, G Latte, E Villa and AJ Ferreri, Salvage chemotherapy with temozolomide in primary CNS lymphomas: preliminary results of a phase II trial. Eur J Cancer 40 (2004) 1682-1688

    Article  PubMed  CAS  Google Scholar 

  26. RH Enting, A Demopoulos, LM Angelis De and LE Abrey, Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide. Neurology 63 (2004) 901-903

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations


Corresponding author

Correspondence to Masato Sakamoto.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sakamoto, M., Oya, N., Mizowaki, T. et al. Initial Experiences of Palliative Stereotactic Radiosurgery for Recurrent Brain Lymphomas. J Neurooncol 77, 53–58 (2006).

Download citation

  • Published:

  • Issue Date:

  • DOI: